{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:05:58Z","timestamp":1778583958832,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.mehy.2012.05.011","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T12:30:33Z","timestamp":1339590633000},"page":"294-298","source":"Crossref","is-referenced-by-count":9,"title":["The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients"],"prefix":"10.1016","volume":"79","author":[{"given":"Adem","family":"Parlak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atila","family":"Iyisoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umit","family":"Aydogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdinc","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"l","key":"10.1016\/j.mehy.2012.05.011_b0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0895-7061(01)02154-9","article-title":"Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making","volume":"14","author":"Cohn","year":"2001","journal-title":"Am J Hypertens"},{"issue":"10","key":"10.1016\/j.mehy.2012.05.011_b0010","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases","volume":"87","author":"Cai","year":"2000","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.mehy.2012.05.011_b0015","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6","article-title":"PTX3 in small vessel vasculitis: an independent indicator of disease activity produced at sides of inflammation","volume":"44","author":"Fazzini","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mehy.2012.05.011_b0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2005.04.040","article-title":"Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension","volume":"46","author":"Perticone","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mehy.2012.05.011_b0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/157340310791162659","article-title":"The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease","volume":"6","author":"Sibal","year":"2010","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1016\/j.mehy.2012.05.011_b0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.ATV.0000252126.48375.d5","article-title":"Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris","volume":"27","author":"Inolue","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mehy.2012.05.011_b0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jinf.2009.11.010","article-title":"Ptx3 predicts severe disease in febril patients at the emergence department","volume":"60","author":"Kruiff","year":"2010","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09231010","article-title":"Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes","volume":"6","author":"Yilmaz","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/ATVBAHA.108.178947","article-title":"Associations pentraxin 3 with cardiovascular disease and all-cause death","volume":"29","author":"Jenny","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.mehy.2012.05.011_b0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mehy.2012.05.011_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.jhh.1001889","article-title":"Targeting endothelial dysfunction in hypertensive subjects","volume":"19","author":"Thuillez","year":"2005","journal-title":"J Hum Hypertens"},{"issue":"5","key":"10.1016\/j.mehy.2012.05.011_b0060","first-page":"128","article-title":"Antihypertensive drug therapy and survival by treatment status in a national survey","volume":"13","author":"Haulik","year":"1989","journal-title":"Hypertension"},{"issue":"21","key":"10.1016\/j.mehy.2012.05.011_b0065","first-page":"1127","article-title":"Endothelial function: a critical determinant in atherosclerosis?","volume":"109","author":"Landmesser","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000107410","article-title":"Improving proteinuria, endothelial functions and asymmetricdimethyl arginine levels in chronic kidney disease: ramipril versus valsartan","volume":"25","author":"Yilmaz","year":"2007","journal-title":"Blood Purif"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.jhh.1001982","article-title":"Evidence for renoprotection by blockade of renin-angiotensin-aldosterone system in hypertension and diabetes","volume":"20","author":"Karalleidde","year":"2006","journal-title":"J Hum Hypertens"},{"issue":"12","key":"10.1016\/j.mehy.2012.05.011_b0080","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.ki.5001983","article-title":"Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis","volume":"70","author":"Aslam","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.mehy.2012.05.011_b0085","first-page":"629","article-title":"Effects of valsartan and indapamide on plasma cytokines in essential hypertension","volume":"31","author":"Xie","year":"2006","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"10","key":"10.1016\/j.mehy.2012.05.011_b0090","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfn230","article-title":"Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy","volume":"23","author":"Galle","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.mehy.2012.05.011_b0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/hc3001.094207","article-title":"Nebivolol reverses endothelial dysfunction in essential hypertension","volume":"104","author":"Tzemos","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mehy.2012.05.011_b0100","first-page":"115","article-title":"Effects of nebivolol on endothelial function and exercise parameters in patient with slow coronary flow","volume":"3","author":"Tiryakioglu","year":"2009","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0105","first-page":"383","article-title":"Effect of nebivolol and metoprolol treatments on serum asymetricdimethylarginine levels in hypertensive patients with type 2 diabetes mellitus","volume":"7","author":"Oguz","year":"2007","journal-title":"Anatolian J Cardiol"},{"issue":"8","key":"10.1016\/j.mehy.2012.05.011_b0110","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/00004872-200108000-00005","article-title":"Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients","volume":"19","author":"Taddei","year":"2001","journal-title":"J Hypertensive"},{"issue":"11","key":"10.1016\/j.mehy.2012.05.011_b0115","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/ajh.2008.260","article-title":"Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients","volume":"21","author":"Pasini","year":"2008","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.mehy.2012.05.011_b0120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.phrs.2007.09.015","article-title":"Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity","volume":"56","author":"Garbin","year":"2007","journal-title":"Pharmacol Res"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2012.05.011_b0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2010.12.001","article-title":"The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats","volume":"54","author":"Wang","year":"2011","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2012.05.011_b0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jash.2010.11.003","article-title":"The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension","volume":"5","author":"Kandavar","year":"2011","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"10.1016\/j.mehy.2012.05.011_b0135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-199957040-00011","article-title":"Nebivolol in the management of essential hypertension: a review","volume":"57","author":"Mc Neely","year":"1999","journal-title":"Drugs"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712002253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712002253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T21:21:43Z","timestamp":1542921703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987712002253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0306987712002253"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2012.05.011","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}